Actualités et publications

News of

Naogen Pharma and Atonco announce the appointment of their new president

NANTES – March 27, 2020 – Naogen Pharma and Atonco announce today that Sylvain Fanier, Msc. EMBA, will take over from Professor Jean-François Chatal as President from March 16, 2020.


Mr. Fanier has devoted his career to overseeing and leading the development of several global medical innovations in the health sector. He brings to the company his leadership in strategy, a global perspective of business and financing, acquired over the past 30 years in large groups such as Johnson and Johnson and CR Bard and in medical startups. Specializing in breakthrough medical innovation, he has supported the success of innovative companies such as Lemerpax, Cardioinsight, Sonoscanner, Soundbite Medical Solutions, Surgivisio and Med-Innov through his consulting company, Novariver.

He obtained a bachelor degree in biochemistry and a master’s degree in biology option physiology at Paul Sabatier University, Toulouse. He also holds an EMBA from ESSEC, Paris, France.

Sylvain is a member of the board of Soundbite Medical Solutions Inc. (Montreal, Canada), and Surgivisio SAS (Grenoble, France).

Jean-Pierre Cabocel, chairman of the board said: “I am delighted that Sylvain is assuming the position of president. I am sure he will play a decisive role in the development and success of Naogen Pharma and Atonco. I am also delighted that Jean-François Chatal remains committed to our developments as co-founder and Chief Medical Offficer ”

“It is an honor to be appointed president of Naogen Pharma and Atonco,” added Mr. Fanier. “With the support of the talented and experienced management team and board of directors, we will optimize our development, strengthen our organization and our partnerships in order to ensure the development, financing and valuation of Naogen-Pharma and Atonco. ”


About Naogen Pharma and Atonco:

Mindful of their responsibilities in improving the well-being and health of patients and with the strength of its team of experts, in physics and nuclear medicine, in research and development, industrialization, clinical research and commercialization, Naogen Pharma SAS and Atonco SAS are developing innovative theranostic radiopharmaceuticals from the “Concept to the Market”.

For more information, please contact Sébastien Avila, vice-president of research and development or Sylvain Fanier, president, Naogen Pharma – Atonco, Pôle Bio Ouest, rue du moulin de la Rousselière, 44 800 Saint Herblain, France